
PMV Pharmaceuticals Inc PMVP.OQ PMVP.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for PMV Pharmaceuticals Inc is for a loss of 37 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 1.1% in the last three months.
Wall Street's median 12-month price target for PMV Pharmaceuticals Inc is $6.00, above its last closing price of $1.00.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.39 | -0.38 | -0.45 | Missed | -18.2 |
Sep. 30 2024 | -0.36 | -0.35 | -0.37 | Missed | -5.4 |
Jun. 30 2024 | -0.35 | -0.35 | -0.02 | Beat | 94.3 |
Mar. 31 2024 | -0.35 | -0.36 | -0.30 | Beat | 16.8 |
Dec. 31 2023 | -0.38 | -0.39 | -0.31 | Beat | 19.7 |
Sep. 30 2023 | -0.45 | -0.45 | -0.34 | Beat | 23.8 |
Jun. 30 2023 | -0.46 | -0.47 | -0.38 | Beat | 20 |
Mar. 31 2023 | -0.44 | -0.46 | -0.42 | Beat | 8.4 |
This summary was machine generated May 5 at 13:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)